首页 | 本学科首页   官方微博 | 高级检索  
检索        

腰高比与超重2型糖尿病视网膜病变相关性研究
引用本文:黄珂,石守森,张艳芳.腰高比与超重2型糖尿病视网膜病变相关性研究[J].国际医药卫生导报,2022,28(9):1195-1199.
作者姓名:黄珂  石守森  张艳芳
作者单位:1郑州大学附属洛阳中心医院内分泌科,洛阳 471000; 2郑州大学附属洛阳中心医院胃肠外科,洛阳 471000
基金项目:河南省医学科技攻关计划联合共建项目(LHGJ20200873); 河南省医学科技攻关项目(212102310193)
摘    要:目的 探讨腰高比(WHtR)与超重2型糖尿病(T2DM)视网膜病变(DR)的相关性。方法 招募2019年11月至2020年8月在郑州大学附属洛阳中心医院内分泌科收治的符合条件的620例超重T2DM者,进行回顾性横断面研究,根据是否合并DR分为单纯超重T2DM组和超重T2DM合并DR组,并收集其一般资料及临床指标等,组间比较用t检验,计数资料组间比较用卡方检验;通过统计学分析WHtR与超重DR的相关性。结果 单纯超重T2DM组男282例,女137例,共419例,占总例数67.6%;超重T2DM合并DR组男104例,女97例,共201例,占总例数32.4%。与单纯超重T2DM组相比,超重T2DM合并DR组男性比例更高(P<0.001),相对更高的身高(P=0.001)、体质量指数(P=0.023),更大的腰围(P=0.001)、臀围(P=0.011)、WHtR(P<0.001),糖尿病病程相对更长(P<0.001),更高的糖化血红蛋白(P<0.001),高血压病的发生率更高(P<0.001)。将单因素中有意义的指标纳入多因素logistic分析模型中,结果提示:性别比值比(OR):0.566,95%置信区间(CI):0.331~0.969,P=0.038)、身高(OR:0.933,95%CI:0.913~0.952,P<0.001)、腰围(OR:1.163,95%CI:1.083~1.249,P<0.001)、WHtR(OR:1.074,95%CI:1.063~1.857,P=0.007)、糖尿病病程(OR:1.056;95%CI:1.027~1.087,P<0.001)、糖化血红蛋白(OR:1.560,95%CI:1.391~1.749,P<0.001)、高血压病(OR:1.478,95%CI:1.323~1.707,P<0.001)可能是超重DR的相关危险因素。结论 WHtR与超重DR具有相关性。

关 键 词:腰高比  2型糖尿病  视网膜病变  超重  危险因素  
收稿时间:2022-01-28

Correlation between waist-to-height ratio and diabetic retinopathy in over-weight patients with type 2 diabetes mellitus
Huang Ke,Shi Shousen,Zhang Yanfang.Correlation between waist-to-height ratio and diabetic retinopathy in over-weight patients with type 2 diabetes mellitus[J].International Medicine & Health Guidance News,2022,28(9):1195-1199.
Authors:Huang Ke  Shi Shousen  Zhang Yanfang
Institution:1Department of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China;  2Department of Gastrointestinal Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China
Abstract:Objective To assess the correlation between waist-to-height ratio (WHtR) and diabetic retinopathy (DR) in over-weight patients with type 2 diabetes mellitus (T2DM). Methods A total of 620 over-weight patients with T2DM treated at Department of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University from November 2019 August 2020 were included for a retrospective cross-sectional study. According to whether they were complicated with DR, the patients were divided into an over-weight T2DM group and an over-weight T2DM combined with DR group. Their general data and clinical indicators were collected. The t test was used for the comparison between the two groups, and the chi-square test was used for the comparison of count data between the two groups. The correlation between WHtR and DR in the over-weight patients with T2DM were statistically analyzed. Results There were 419 cases (67.6%) in the over-weight T2DM group, including 282 males and 137 females; there were 201 cases (32.4%) in the over-weight T2DM combined with DR group, including 104 males and 97 females. Compared with the over-weight T2DM group, the over-weight T2DM combined with DR group had a higher proportion of men (P<0.001), relatively higher height (P=0.001), higher body mass index (BMI) (P=0.023), larger waist circumference (P=0.001), larger hip circumference (P=0.011), higher WHtR (P<0.001), relatively longer duration of T2DM (P<0.001), higher HbA1c (P<0.001), and a higher incidence of hypertension (P<0.001). The multivariate logistic regression analysis showed that gender (OR=0.566, 95%CI 0.331-0.969, P=0.038), height (OR=0.933,95%CI 0.913-0.952, P<0.001), waist circumference (OR=1.163, 95%CI 1.083-1.249, P<0.001), WHtR (OR=1.074, 95%CI 1.063-1.857, P=0.007), T2DM course (OR=1.056, 95%CI 1.027-1.087, P<0.001), HbA1c (OR=1.560, 95%CI 1.391-1.749, P<0.001), hypertension (OR=1.478, 95%CI 1.323-1.707, P<0.001) might be the associated risk factors with DR in the over-weight patients with T2DM. Conclusion WHtR is associated with DR in over-weight patients with T2DM.
Keywords:Waist-to-height ratio  Type 2 diabetes mellitus  Retinopathy  Over-weight  Risk factors
本文献已被 万方数据 等数据库收录!
点击此处可从《国际医药卫生导报》浏览原始摘要信息
点击此处可从《国际医药卫生导报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号